Blurbs

Analysts Are Neutral on These Healthcare Stocks: Amgen (AMGN), Regeneron (REGN)

Analysts fell to the sidelines weighing in on Amgen (AMGNResearch Report) and Regeneron (REGNResearch Report) with neutral ratings, indicating that the experts are neither bullish nor bearish on the stocks.

Amgen (AMGN)

RBC Capital analyst Gregory Renza maintained a Hold rating on Amgen on November 15 and set a price target of $255.00. The company’s shares closed last Wednesday at $283.77, close to its 52-week high of $296.67.

According to TipRanks.com, Renza is a 1-star analyst with an average return of -1.5% and a 35.5% success rate. Renza covers the Healthcare sector, focusing on stocks such as Verrica Pharmaceuticals, Prometheus Biosciences, and Pacira Pharmaceuticals.

Currently, the analyst consensus on Amgen is a Hold with an average price target of $261.08, a -8.1% downside from current levels. In a report issued on November 3, SVB Securities also maintained a Hold rating on the stock.

See today’s best-performing stocks on TipRanks >>

Regeneron (REGN)

RBC Capital analyst Brian Abrahams maintained a Hold rating on Regeneron on November 15 and set a price target of $745.00. The company’s shares closed last Wednesday at $735.67, close to its 52-week high of $769.63.

According to TipRanks.com, Abrahams is a 5-star analyst with an average return of 8.1% and a 51.5% success rate. Abrahams covers the Healthcare sector, focusing on stocks such as Intra-Cellular Therapies, Karyopharm Therapeutics, and Vertex Pharmaceuticals.

Regeneron has an analyst consensus of Moderate Buy, with a price target consensus of $813.00, which is a 10.6% upside from current levels. In a report issued on November 3, J.P. Morgan also maintained a Hold rating on the stock with a $750.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on AMGN:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More